| Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia JC Byrd, B Harrington, S O’Brien, JA Jones, A Schuh, S Devereux, ... New England Journal of Medicine 374 (4), 323-332, 2016 | 1021 | 2016 |
| PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD BM Haverkos, D Abbott, M Hamadani, P Armand, ME Flowers, ... Blood, The Journal of the American Society of Hematology 130 (2), 221-228, 2017 | 281 | 2017 |
| Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib FT Awan, A Schuh, JR Brown, RR Furman, JM Pagel, P Hillmen, ... Blood advances 3 (9), 1553-1562, 2019 | 203 | 2019 |
| Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results JC Byrd, WG Wierda, A Schuh, S Devereux, JM Chaves, JR Brown, ... Blood, The Journal of the American Society of Hematology 135 (15), 1204-1213, 2020 | 183 | 2020 |
| How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia DM Stephens, JC Byrd Blood, The Journal of the American Society of Hematology 133 (12), 1298-1307, 2019 | 140 | 2019 |
| Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in oncology WG Wierda, JC Byrd, JS Abramson, SF Bilgrami, G Bociek, D Brander, ... Journal of the National Comprehensive Cancer Network 18 (2), 185-217, 2020 | 130 | 2020 |
| Outcomes of adults and children with primary mediastinal B‐cell lymphoma treated with dose‐adjusted EPOCH‐R L Giulino‐Roth, T O'Donohue, Z Chen, NL Bartlett, A LaCasce, ... British journal of haematology 179 (5), 739-747, 2017 | 129 | 2017 |
| Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma DM Stephens, H Li, H Schöder, DJ Straus, CH Moskowitz, M LeBlanc, ... Blood, The Journal of the American Society of Hematology 134 (15), 1238-1246, 2019 | 112 | 2019 |
| Continued risk of relapse independent of treatment modality in limited-stage diffuse large B-cell lymphoma: final and long-term analysis of Southwest Oncology Group Study S8736 DM Stephens, H Li, ML LeBlanc, SD Puvvada, D Persky, JW Friedberg, ... Journal of Clinical Oncology 34 (25), 2997-3004, 2016 | 110 | 2016 |
| Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL T Siddiqi, JD Soumerai, KA Dorritie, DM Stephens, PA Riedell, J Arnason, ... Blood, The Journal of the American Society of Hematology 139 (12), 1794-1806, 2022 | 96 | 2022 |
| Positron emission tomography–directed therapy for patients with limited-stage diffuse large B-cell lymphoma: results of intergroup national clinical trials network study S1001 DO Persky, H Li, DM Stephens, SI Park, NL Bartlett, LJ Swinnen, PM Barr, ... Journal of Clinical Oncology 38 (26), 3003-3011, 2020 | 93 | 2020 |
| Acalabrutinib in treatment-naive chronic lymphocytic leukemia JC Byrd, JA Woyach, RR Furman, P Martin, S O’Brien, JR Brown, ... Blood, The Journal of the American Society of Hematology 137 (24), 3327-3338, 2021 | 86 | 2021 |
| Final results of phase 1, dose escalation study evaluating ARQ 531 in patients with relapsed or refractory B-cell lymphoid malignancies J Woyach, DM Stephens, IW Flinn, SA Bhat, RE Savage, F Chai, ... Blood 134, 4298, 2019 | 85 | 2019 |
| A single‐institution retrospective cohort study of first‐line R‐EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as … KA Rogers, Y Huang, AS Ruppert, G Salem, DM Stephens, NA Heerema, ... British journal of haematology 180 (2), 259-266, 2018 | 72 | 2018 |
| Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions VM Orellana-Noia, DR Reed, AA McCook, JM Sen, CM Barlow, ... Blood, The Journal of the American Society of Hematology 139 (3), 413-423, 2022 | 67 | 2022 |
| Transcend CLL 004: phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia … WG Wierda, KA Dorritie, J Munoz, DM Stephens, SR Solomon, ... Blood 136, 39-40, 2020 | 66 | 2020 |
| NCCN guidelines® insights: Chronic Lymphocytic leukemia/small Lymphocytic lymphoma, version 3.2022: Featured updates to the NCCN Guidelines WG Wierda, J Brown, JS Abramson, F Awan, SF Bilgrami, G Bociek, ... Journal of the National Comprehensive Cancer Network 20 (6), 622-634, 2022 | 60 | 2022 |
| Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study T Siddiqi, DG Maloney, SS Kenderian, DM Brander, K Dorritie, ... The Lancet 402 (10402), 641-654, 2023 | 47 | 2023 |
| NCCN guidelines insights: chronic lymphocytic leukemia/small lymphocytic lymphoma, version 2.2019 WG Wierda, JC Byrd, JS Abramson, SF Bilgrami, G Bociek, D Brander, ... Journal of the National Comprehensive Cancer Network 17 (1), 12-20, 2019 | 46 | 2019 |
| Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia CM Cheney, DM Stephens, X Mo, S Rafiq, J Butchar, JM Flynn, JA Jones, ... MAbs 6 (3), 748-754, 2014 | 45 | 2014 |
